Our goal is to cost-effectively develop and commercialize novel therapies that will provide safe, substantial and sustained analgesia, or pain relief. Initially, we intend to develop a diverse portfolio of product candidates for the treatment of OA pain where we believe there is a significant unmet need. The principal elements of our strategy to accomplish this goal are the following:
Focus on novel product candidates that provide long-lasting analgesia locally while avoiding systemic side effects. We intend to develop anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. Many OA patients will eventually require IA injection therapies to control their pain as the disease progresses. We believe there is a significant unmet medical need for persistent, effective and safe OA pain relief that can be addressed by IA sustained-release injection therapies.
Mitigate development risk and expedite regulatory timeline to product approval. We seek to mitigate development risk by selecting product candidates with validated mechanisms of action. Each of our product candidates also utilizes a unique mechanism of action for achieving analgesia and/or anti-inflammatory effects, which diversifies development risk across multiple targets.
Target multiple points in the OA pain treatment spectrum. To maximize the likelihood of bringing products to market successfully, each of our three product candidates targets different elements of the OA treatment continuum.
Retain commercial rights in the United States and selectively partner outside of the United States. Because IA therapies in the United States are administered by a relatively small number of specialists, particularly orthopedists and rheumatologists, we believe that we can cost-effectively commercialize our product candidates, if approved, with our own specialty sales and marketing organization in the United States, and thereby retain more of the commercial value of these product candidates.
Leverage our management team’s expertise to develop and commercialize our product portfolio. Our co-founders, Dr. Clayman and Dr. Bodick, have significant capability, developed during their combined 35 years at Eli Lilly and Company, in both rapidly progressing new drugs to meaningful clinical proof of concept and in conducting successful pivotal registration programs. Our senior management team includes members who are highly capable in the design and implementation of efficient and effective drug development programs and who have experience building sales forces and bringing new therapies to market.